Goodpasture Syndrome

Goodpasture Syndrome (anti-GBM disease) is a rare but life-threatening autoimmune condition in which the immune system produces antibodies against the glomerular basement membrane of the kidneys and the alveolar basement membrane of the lungs. Without emergency treatment, it can destroy kidney function within days and cause fatal pulmonary hemorrhage. Early recognition and rapid plasma exchange with immunosuppression can prevent dialysis-dependence and death.

Overview and History
Epidemiology
Pathophysiology: The Anti-GBM Antigen
Clinical Presentation
Diffuse Alveolar Hemorrhage
Rapidly Progressive Glomerulonephritis
Diagnosis
Double-Positive ANCA + Anti-GBM Disease
Treatment
Prognosis and Outcomes
Research Papers (PubMed searches)
References
Connections
Featured Videos

1. Overview and History

Goodpasture Syndrome—now more precisely called anti-glomerular basement membrane (anti-GBM) disease—is defined by circulating IgG autoantibodies directed against the α3 chain of type IV collagen, the major structural protein of the glomerular basement membrane (GBM) and alveolar basement membrane (ABM). The result is a pulmonary-renal syndrome: simultaneous or sequential diffuse alveolar hemorrhage (DAH) and rapidly progressive crescentic glomerulonephritis (RPGN).

The condition is named after Ernest Goodpasture, an American pathologist at Vanderbilt University who in 1919—during the influenza pandemic—described a young man who died of pulmonary hemorrhage and glomerulonephritis. Goodpasture suspected a link between influenza and a hemorrhagic nephritis syndrome. Stanton and Tange coined the eponym "Goodpasture's syndrome" in 1958 for the clinical triad of pulmonary hemorrhage, glomerulonephritis, and anemia. The autoimmune mechanism—the anti-GBM antibody—was identified in the 1960s by Lerner, Glassock, and Dixon using immunofluorescence studies, which revealed the pathognomonic linear IgG deposits along the GBM.

Back to Table of Contents

2. Epidemiology

Anti-GBM disease is rare: incidence 1–2 cases per million population per year, accounting for approximately 10–15% of all RPGN cases and 1–5% of all biopsy-proven glomerulonephritis. Despite its rarity, it is one of the most feared causes of RPGN because of its rapid, destructive course.

There is a bimodal age distribution:

First peak: age 18–30 years. Predominantly male. Pulmonary hemorrhage (DAH) is prominent. Exposure to cigarette smoke and organic solvents is particularly important in triggering lung involvement in this group.
Second peak: age 60–70 years. More equal sex distribution, or slight female predominance. Renal-dominant presentation with less pulmonary involvement. This older peak is increasingly recognized with wider use of anti-GBM antibody testing.

Genetic susceptibility: HLA-DRB1*15:01 (formerly DR2) is strongly associated with anti-GBM disease (odds ratio ~6); HLA-DRB1*01:01 and *03:01 confer partial susceptibility. These HLA molecules are thought to present the Goodpasture antigen (the NC1 domain of α3[IV] collagen) to autoreactive T cells, breaking peripheral tolerance.

Environmental triggers: Cigarette smoking (dramatically increases risk of DAH in genetically susceptible individuals by exposing alveolar capillary BM to the immune system), hydrocarbon solvent inhalation, cocaine inhalation, viral upper respiratory tract infections, and rarely, drugs (penicillamine, hydralazine, alemtuzumab). Infection-triggered molecular mimicry has been proposed, aligning with Goodpasture's original influenza-era observation.

Back to Table of Contents

3. Pathophysiology: The Anti-GBM Antigen

The target antigen in Goodpasture Syndrome is the NC1 domain of the α3 chain of type IV collagen—referred to as the Goodpasture antigen. Type IV collagen is the principal scaffolding of all basement membranes throughout the body, but the specific α3α4α5 network formed by α3, α4, and α5 chains is found almost exclusively in the glomerular basement membrane (GBM), the alveolar basement membrane (ABM), the cochlear basement membrane, and the lens capsule. This explains why anti-GBM disease injures the kidneys and lungs specifically.

Within the GBM, the α3NC1 domain is normally cryptic—buried within the α3α4α5 hexameric network and inaccessible to circulating antibodies. Environmental insults (smoking, solvents, infections) are believed to disrupt this quaternary structure, exposing cryptic epitopes (the Eα and Eβ epitopes within α3NC1) and initiating an autoimmune response in genetically susceptible individuals.

Autoantibody-mediated injury cascade:

IgG anti-GBM antibodies (predominantly IgG1 and IgG3 subclasses) bind linearly along the GBM, activating the classical complement pathway (C3, C5b–9 membrane attack complex).
Complement activation recruits neutrophils and monocytes, which release proteases (MMP-2, MMP-9) and reactive oxygen species, causing fibrinoid necrosis of the glomerular capillary wall.
Parietal epithelial cells (podocyte precursors) on Bowman's capsule proliferate and accumulate fibrin, forming the characteristic cellular crescents (fibrocellular crescents in early disease, fibrous crescents in late disease).
Crescents compress the glomerular tuft, obliterate filtration, and cause the precipitous GFR loss of RPGN.
In the lung, anti-GBM IgG binds alveolar basement membrane, but pulmonary hemorrhage requires an additional "second hit"—typically smoking or an inflammatory stimulus—because the alveolar BM is normally shielded from circulating antibodies by intact alveolar epithelium. Smoking disrupts this barrier, enabling antibody access and complement-mediated alveolar capillaritis.

Back to Table of Contents

4. Clinical Presentation

Patients with Goodpasture Syndrome typically present with a dramatic, rapidly evolving illness over days to a few weeks. The classic triad is hemoptysis, hematuria, and rapidly rising creatinine. Constitutional symptoms (fatigue, low-grade fever, weight loss) may precede the acute presentation by weeks.

Three presentation patterns:

Pulmonary-renal syndrome (~50% of cases): Both DAH and crescentic GN present simultaneously or within days of each other. The most dramatic and dangerous form.
Renal-limited disease (~30–40%): Anti-GBM antibodies attack the GBM only, with no clinically apparent pulmonary hemorrhage. Often presents as isolated RPGN. More common in the older age peak and in non-smokers.
Pulmonary-limited disease (~10–20%): DAH with minimal or no renal involvement at presentation. Rare; may progress to renal disease.

Because renal function can fall from normal to dialysis-requiring within days, any patient presenting with hemoptysis plus hematuria or rapidly rising creatinine must be evaluated urgently for anti-GBM disease. Delays in diagnosis are the primary cause of preventable dialysis-dependence.

Back to Table of Contents

5. Diffuse Alveolar Hemorrhage

Pulmonary involvement in Goodpasture Syndrome produces diffuse alveolar hemorrhage (DAH)—widespread bleeding into the alveolar spaces from alveolar capillaritis. This is distinct from focal pulmonary hemorrhage or bronchial bleeding.

Symptoms:

Hemoptysis: Ranges from blood-tinged sputum to massive, life-threatening hemoptysis. Approximately 30% of patients with DAH have no hemoptysis at presentation, making diagnosis dependent on imaging and BAL.
Dyspnea and hypoxia: Often rapidly progressive; may require mechanical ventilation.
Fatigue and pallor: Due to iron-deficiency anemia from alveolar blood sequestration.

Imaging: Chest X-ray and CT show bilateral, diffuse alveolar consolidation in a perihilar or basilar distribution, often "bat-wing" in pattern. Pleural effusions are uncommon.

Paradoxically elevated DLCO: The carbon monoxide diffusing capacity (DL_CO) is paradoxically elevated in alveolar hemorrhage because hemoglobin in the alveolar space avidly absorbs the inhaled CO tracer. A DL_COco above the upper limit of normal in the setting of bilateral infiltrates and hypoxia is strongly suggestive of alveolar hemorrhage.

Bronchoalveolar lavage (BAL): Diagnostically essential when hemoptysis is absent or imaging is ambiguous. DAH is confirmed by sequentially hemorrhagic returns from BAL (each successive aliquot is bloodier than the last, or the third aliquot is at least as bloody as the first) plus hemosiderin-laden macrophages (siderophages) on cytology, indicating hemorrhage for ≥48–72 hours.

Smoking is the critical trigger for pulmonary involvement. In Goodpasture Syndrome, virtually all patients with DAH are current or former smokers. The alveolar epithelial barrier—which normally prevents circulating anti-ABM antibodies from reaching the basement membrane—is disrupted by cigarette smoke oxidants. Smoking cessation is therefore critical.

Back to Table of Contents

6. Rapidly Progressive Glomerulonephritis

The renal injury in Goodpasture Syndrome is the most severe form of glomerulonephritis: crescentic GN (RPGN Type I). Without treatment, renal function can fall to dialysis-requiring levels within 24–72 hours of presentation.

Urinary findings: Macroscopic or microscopic hematuria with dysmorphic red blood cells and red blood cell casts on urine microscopy (the hallmark of glomerular bleeding), proteinuria (usually non-nephrotic range, <3 g/day), and oliguria/anuria as disease progresses.

Serum creatinine: Rises rapidly—the rate of rise (often 0.5–2 mg/dL per day) distinguishes RPGN from other kidney diseases. By the time the patient presents, creatinine may already be severely elevated.

Kidney biopsy findings:

Light microscopy: Fibrocellular crescents in >50% of glomeruli (often >80%). Fibrinoid necrosis of the glomerular tuft. The crescents are composed of proliferating parietal epithelial cells, macrophages, and fibrin.
Immunofluorescence (IF): The pathognomonic finding is linear IgG deposits along the GBM—a smooth, continuous "paintbrush" or "railroad track" pattern staining the entire GBM. Linear C3 deposits accompany the IgG. This is strikingly different from the granular ("lumpy-bumpy") pattern of immune complex diseases (IgAN, membranous nephropathy, lupus) or the pauci-immune pattern of ANCA vasculitis.
Electron microscopy: No electron-dense immune complex deposits (distinguishing it from granular immune complex GN). The GBM may show focal disruption.

The proportion of crescents on biopsy is the single most important predictor of renal outcome. When >85% of glomeruli have crescents and the patient is already dialysis-dependent at presentation, renal recovery with treatment is uncommon, though treatment is still indicated to halt further injury and prevent relapse.

Back to Table of Contents

7. Diagnosis

Goodpasture Syndrome is diagnosed by the combination of clinical presentation, serology, and kidney (or lung) biopsy. Do not delay treatment to await biopsy results in a deteriorating patient.

1. Serum anti-GBM antibodies (cornerstone of diagnosis):

Detected by ELISA using purified α3NC1 antigen. Sensitivity >95%, specificity >90%.
IgG class; titer at presentation does not reliably predict severity, but trend toward negativity correlates with treatment response.
A positive anti-GBM antibody in the context of RPGN or DAH is sufficient to initiate treatment while awaiting biopsy.
Commercial kits vary in sensitivity; false negatives occur with some assays. If clinical suspicion is high and initial ELISA is negative, consider repeating with an alternative assay or proceeding to biopsy.

2. Kidney biopsy: Definitive. Confirms linear IgG on IF and quantifies crescent burden (critical for prognosis). Also identifies co-existing pathology (ANCA vasculitis in double-positive patients).

3. ANCA testing (essential—see next section): MPO-ANCA and PR3-ANCA by ELISA or CLIA. Present in 30–40% of anti-GBM cases (double-positive). Must be tested in all anti-GBM patients.

4. Urinalysis with microscopy: RBC casts confirm glomerular bleeding. Dipstick hematuria and proteinuria quantification.

5. Serum creatinine and eGFR trend: Rate of rise is diagnostically informative. BMP/CMP daily in acute phase.

6. Chest imaging and BAL: CXR; CT chest when DAH suspected. BAL if hemoptysis absent but pulmonary infiltrates present—confirms DAH by hemorrhagic return and siderophages.

7. Complement levels: Usually normal (unlike lupus nephritis). Normal C3/C4 with linear IF pattern distinguishes anti-GBM disease from complement-consuming immune complex GN.

Back to Table of Contents

8. Double-Positive ANCA + Anti-GBM Disease

Approximately 30–40% of patients with anti-GBM disease are ANCA-positive—a phenomenon called "double-positive" disease. The most common combination is MPO-ANCA (pANCA) + anti-GBM, though PR3-ANCA + anti-GBM occurs as well.

Double-positive disease is clinically significant for several reasons:

Worse renal prognosis than anti-GBM alone or ANCA vasculitis alone.
ANCA vasculitis component may relapse after the anti-GBM antibodies become negative. Anti-GBM disease itself rarely relapses once antibodies are cleared, but ANCA disease can smolder and recur—requiring long-term maintenance immunosuppression analogous to AAV (ANCA-associated vasculitis) protocols.
Treatment must address both conditions: plasma exchange (for anti-GBM), cyclophosphamide, and corticosteroids as in single-positive disease; continued rituximab maintenance considered for the ANCA component.
Pathogenically, it is hypothesized that anti-GBM antibodies may unmask MPO or PR3 antigens through GBM destruction, or that an underlying susceptibility to autoimmunity predisposes to both.

Conversely, 15–20% of ANCA-positive AAV patients have co-existing anti-GBM antibodies. This bidirectional association reinforces the need to test for both autoantibodies in any patient presenting with RPGN or pulmonary-renal syndrome.

Back to Table of Contents

9. Treatment

Treatment of Goodpasture Syndrome is a medical emergency. Every day—and every hour in severe cases—of delay allows additional crescents to form and irreversible nephrons to be destroyed. Standard therapy combines plasma exchange (to rapidly remove circulating antibodies) with immunosuppression (to prevent antibody rebound).

1. Plasma exchange (plasmapheresis)—URGENT:

4–5 liters per session, replaced with 5% albumin (fresh frozen plasma used when there is active DAH, to replace clotting factors).
Daily sessions for 14 days, or until anti-GBM antibody becomes undetectable by ELISA on two consecutive measurements.
Mechanism: removes circulating IgG anti-GBM antibodies (each session removes ~70% of intravascular IgG), buying time for immunosuppression to suppress new antibody production.
Most effective if started before dialysis-dependence and when crescent burden is <85%. Patients already requiring dialysis with >85% crescents rarely recover renal function, but plasma exchange is still given to treat DAH and prevent further injury.

2. Cyclophosphamide—suppresses antibody production:

Oral cyclophosphamide 2 mg/kg/day (capped at 150 mg/day; reduce by 25% if age >55 or eGFR <10 mL/min) for 3 months.
Prevents rebound antibody synthesis after plasmapheresis ends.
Monitor CBC weekly; hold if WBC <3,000/μL. Mesna co-administration for bladder protection at higher doses. Pneumocystis prophylaxis with trimethoprim-sulfamethoxazole.

3. Corticosteroids—anti-inflammatory:

Methylprednisolone IV 500–1000 mg/day × 3 days (pulse), then oral prednisolone 1 mg/kg/day (max 60–80 mg/day), tapering over 6 months.
Reduces complement-mediated inflammatory injury and suppresses the cellular arm of the immune response.

4. Monitoring anti-GBM titers: Check anti-GBM antibody by ELISA every 1–2 weeks during active treatment. Rising titers indicate inadequate suppression. Aim for sustained negativity before considering de-escalation.

5. Rituximab (emerging for refractory or double-positive disease):

Anti-CD20 monoclonal antibody depleting B cells, reducing antibody production.
Used in refractory anti-GBM disease (persistent antibody despite standard therapy) or for the ANCA component in double-positive patients who require maintenance therapy.
Standard ANCA dosing: 375 mg/m² weekly × 4, or 1000 mg × 2 doses two weeks apart.

6. Smoking cessation (mandatory): Smoking is the primary trigger for pulmonary hemorrhage in Goodpasture Syndrome. Cessation dramatically reduces the risk of DAH recurrence and is a condition for proceeding to any elective interventions.

7. Dialysis: Acute hemodialysis or CRRT for oliguria, hyperkalemia, acidosis, or fluid overload. Anti-GBM disease patients frequently require dialysis acutely but may recover renal function with treatment.

8. Renal transplantation: Safe and standard-of-care for anti-GBM disease patients who progress to ESRD. Transplant should be delayed until anti-GBM antibodies are undetectable for at least 6–12 months, as circulating antibodies will attack the transplanted kidney's normal α3α4α5 network. Once antibodies are negative, recurrence of anti-GBM disease in the transplant is rare (<5%). The delay to transplant has no adverse effect on outcomes.

9. Anti-GBM recurrence: Unlike ANCA vasculitis, anti-GBM disease is a monophasic illness that rarely relapses once antibodies clear. Long-term immunosuppressive maintenance is not required for isolated anti-GBM disease. Relapse should prompt testing for double-positive disease (ANCA) or an alternate diagnosis.

Back to Table of Contents

10. Prognosis and Outcomes

Prognosis in Goodpasture Syndrome has improved substantially since the introduction of plasma exchange in the 1970s. Prior to plasmapheresis, mortality was >50% and dialysis-dependence was near-universal in those who survived. With modern intensive treatment:

Patient survival at 1 year: ~80–90%. Death is usually from pulmonary hemorrhage (in untreated or late-treated cases) or infectious complications of immunosuppression.
Renal outcomes are critically dependent on timing of treatment and crescent burden at biopsy:

Predictors of good renal outcome:

Creatinine <5.7 mg/dL at presentation
Not requiring dialysis at start of treatment
<50% crescents on biopsy
Early initiation of plasma exchange
Absence of oligoanuria

Predictors of poor renal outcome (ESRD likely despite treatment):

Dialysis-dependent at presentation
>85% crescents on biopsy (most studies show <10% renal recovery in this group)
Creatinine >6–7 mg/dL at start of treatment
Oligoanuria

Even in patients with poor predicted renal outcomes, treatment is indicated to manage life-threatening DAH and to prevent antibody-mediated injury to any residual functioning nephrons. Some patients with apparent "dialysis-dependent at biopsy" status do recover enough renal function to come off dialysis with aggressive treatment.

Anti-GBM disease is monophasic and rarely relapses. Once serum anti-GBM antibodies are persistently negative, the immunosuppression can be safely tapered and discontinued. Patients should be counseled to avoid smoking permanently, as re-exposure can potentially re-trigger pulmonary involvement through alveolar barrier disruption.

Back to Table of Contents

11. Research Papers (PubMed searches)

Back to Table of Contents

12. References

Goodpasture EW. The significance of certain pulmonary lesions in relation to the etiology of influenza. Am J Med Sci. 1919;158(6):863–870. https://doi.org/10.1097/00000441-191912000-00012
Stanton MC, Tange JD. Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). Australas Ann Med. 1958;7(2):132–144. PMID: 13546875. https://doi.org/10.1111/imj.1958.7.2.132
Lerner RA, Glassock RJ, Dixon FJ. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J Exp Med. 1967;126(6):989–1004. PMID: 4168715. https://doi.org/10.1084/jem.126.6.989
Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512–1523. PMID: 9366583. https://doi.org/10.1056/NEJM199711203372106
Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033–1042. PMID: 11388816. https://doi.org/10.7326/0003-4819-134-11-200106050-00009
Pusey CD. Anti-glomerular basement membrane disease. Kidney Int. 2003;64(4):1535–1550. PMID: 12969178. https://doi.org/10.1046/j.1523-1755.2003.00241.x
Hellmark T, Segelmark M. Diagnosis and classification of Goodpasture's disease (anti-GBM). J Autoimmun. 2014;48–49:108–112. PMID: 24602352. https://doi.org/10.1016/j.jaut.2014.01.024
McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017;12(7):1162–1172. PMID: 28550082. https://doi.org/10.2215/CJN.01380217
Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89(4):897–908. PMID: 26994575. https://doi.org/10.1016/j.kint.2015.12.051
Jain R, Smith S, Bhaskaran M, Jhaveri KD. Goodpasture syndrome. Kidney Int Rep. 2021;6(3):535–545. PMID: 33732991. https://doi.org/10.1016/j.ekir.2020.12.039
Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164–1177. PMID: 12631105. https://doi.org/10.1046/j.1523-1755.2003.00843.x
Turner N, Mason PJ, Brown R, et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest. 1992;89(2):592–601. PMID: 1737845. https://doi.org/10.1172/JCI115625

Back to Table of Contents

Connections

↑ Back to Table of Contents